Claritin-D adds asthma safety labeling; Hoechst and Schering settle in Claritin ad dispute.
Executive Summary
SCHERING-PLOUGH CLARITIN-D ADDS ASTHMA SAFETY DATA TO LABELING Feb. 5: the company announced that it is updating the Claritin-D label with information regarding the safety of its loratadine/pseudoephedrine product in seasonal allergic rhinitis patients with concomitant asthma. Prescribing information for Claritin-D now lists results of a study in patients with asthma and states: "This supports the safety of administering Claritin-D to seasonal allergic rhinitis patients with asthma." In the six-week, placebo-controlled study, patients with rhinitis and mild-to-moderate asthma had improvements in allergy symptoms with no decrease in pulmonary function, Schering reported.